Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.06 USD
0.00 (-2.00%)
Updated May 1, 2024 03:39 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARDS 0.06 0.00(-2.00%)
Will ARDS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARDS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARDS
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
ARDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
Other News for ARDS
Aridis Pharmaceuticals Inc To Provide a Business and Pipeline Update Transcript
Aridis Pharmaceuticals Inc Investor Update Call Transcript